GOP vs. Trump: The Fight Over Cannabis Rescheduling Powers

A Party at War With Itself on Cannabis

In one of the more unusual political dynamics of 2026, a significant bloc of Republican lawmakers is actively working to reverse a signature policy move by a Republican president. Nearly 50 GOP legislators are fighting to strip the White House of its authority to reschedule controlled substances — specifically to undo the Trump administration's April 23 decision to move certain cannabis products to Schedule III.

The conflict illuminates a fundamental tension within the Republican Party between executive power, states' rights, law-and-order ideology, and the growing political reality that cannabis legalization commands majority support across the political spectrum.

What Trump Did and Why It Matters

On April 23, 2026, Acting Attorney General Todd Blanche signed two orders placing FDA-approved marijuana products and state-licensed medical cannabis in Schedule III of the Controlled Substances Act. The move fulfilled a campaign promise Trump made during the 2024 election, when he recognized that cannabis reform had become a bipartisan issue with broad popular appeal.

The reclassification carries enormous practical consequences. Schedule III status means medical cannabis businesses can finally deduct ordinary business expenses on federal taxes — a change that could save the industry billions annually by eliminating the punitive effects of IRS Section 280E. It also opens pathways for legitimate banking relationships and potentially simplifies interstate commerce.

The Congressional Counteroffensive

The pushback was swift. A House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies approved a funding bill containing language that would block the Department of Justice from exercising its authority to reclassify cannabis. The vote split along party lines: 8-6, with all Republican members voting to strip the executive branch of rescheduling power.

The bill is scheduled for markup by the full House Appropriations Committee on May 13, where it will face a broader vote before potentially reaching the House floor. If the language survives the full appropriations process and is signed into law, it would effectively freeze cannabis at its current classification regardless of executive action.

The Legal Theory: Who Controls Scheduling?

The constitutional question at the heart of this fight is whether the authority to schedule, reschedule, or deschedule substances belongs to the executive branch (through the Attorney General and DEA) or the legislative branch (through Congress).

Currently, the Controlled Substances Act delegates scheduling authority to the Attorney General, with the DEA handling implementation. Republican opponents argue this delegation was never intended to allow wholesale policy changes of this magnitude without direct congressional approval. They want to reserve rescheduling authority exclusively for legislative action.

Supporters of executive authority point out that the same delegation has been used for decades without challenge — including to schedule new synthetic drugs, reschedule prescription medications, and adjust classifications based on emerging science. Restricting this authority solely for cannabis would be unprecedented.

Who Are the Opponents?

The anti-rescheduling bloc includes lawmakers from several overlapping constituencies. Social conservatives object on moral grounds, viewing cannabis legalization as part of a broader cultural decline. Law-and-order Republicans worry about the message that reclassification sends about drug enforcement. Pharmaceutical-sector allies have financial interests in maintaining barriers to cannabis market entry. And some federalism purists genuinely believe Congress should make this decision, regardless of their stance on cannabis itself.

Notably absent from the opposition: most Republican lawmakers from states with active cannabis markets. Representatives from Ohio, Florida, Arizona, and other states with legal cannabis generally recognize that their constituents benefit from the rescheduling.

Previous Attempts and Their Failures

This is not the first time congressional Republicans have attempted to block cannabis rescheduling. Earlier in 2026, similar language was included in proposed appropriations bills but was ultimately stripped from the final bipartisan spending package that passed the House 397-28 and the Senate 82-15 on January 15.

The bipartisan margins of those votes suggest that anti-rescheduling provisions face an uphill battle in any bill that must attract Democratic support to pass. However, the appropriations process offers multiple opportunities for individual provisions to be included in must-pass legislation, creating ongoing uncertainty for the cannabis industry.

Industry Response and Market Impact

The cannabis industry is watching the congressional maneuvering with a mixture of concern and confidence. Most legal analysts believe the appropriations rider has a low probability of surviving the full legislative process — but even the possibility of reversal creates uncertainty that affects investment decisions, business planning, and stock valuations.

Cannabis companies that had already begun adjusting their tax planning to account for 280E relief may find themselves in limbo if the appropriations fight extends through the fiscal year. The uncertainty itself carries economic costs, regardless of the eventual outcome.

The Political Calculation

For Trump, cannabis rescheduling was a calculated political move. Polling consistently shows that 70% or more of Americans support some form of cannabis legalization, and the issue cuts across party lines. By acting on rescheduling, Trump positioned himself as responsive to popular will while also delivering tangible benefits to a growing industry.

For the Republican opponents, the calculation is different. Their primary voters — older, more rural, more socially conservative — are the demographic least likely to support cannabis reform. In safely red districts, opposing cannabis carries minimal political risk while signaling alignment with traditional values.

What Happens Next

The May 13 full Appropriations Committee markup will be the next critical inflection point. If the anti-rescheduling language survives, it will still need to pass the full House, survive Senate negotiations, and avoid a presidential veto — a gauntlet that makes final enactment unlikely but not impossible.

More probable is that the provision becomes a bargaining chip in broader budget negotiations, eventually traded away for other priorities. But the persistence of the effort — and the willingness of nearly 50 Republicans to publicly oppose their own president on this issue — signals that federal cannabis policy will remain contested terrain regardless of executive action. The same fault line is showing up in red-state governors' offices, where Indiana's Mike Braun is signaling openness to medical cannabis after years of party orthodoxy.

The fight over rescheduling powers is ultimately a fight over the pace of cannabis reform. The question is not whether cannabis policy will continue to liberalize — the trend is clear and probably irreversible — but how quickly, through what mechanisms, and with what safeguards. On that question, the Republican Party remains deeply divided with itself.

For background on the House appropriations vote that triggered this constitutional fight, see: GOP vs. Trump on Cannabis: House Defies Rescheduling 2026.

While Washington argues over who has the authority to reschedule, state-licensed retail keeps moving. You can find a dispensary near you today and check live menus from operators who don't have to wait on the May 13 markup to keep the shelves stocked.